Affimed (AFMD) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Affimed has reported promising results from their AFM24-102 study for treating non-small cell lung cancer, revealing a 73.3% disease control rate and a median progression-free survival of 5.9 months among evaluable patients. These findings, particularly significant for patients previously resistant to existing treatments, will be detailed at the ASCO Annual Meeting and further discussed in an upcoming company webcast.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.